Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22232508 | 1.00 | PNMT (0.43) | PNMTMPOTAAR1ADCY10GRIN2B | |
| SCHEMBL22232600 | 0.86 | TAAR1 (0.45) | MPOTAAR1ADCY10IDO1AGXT | |
| SCHEMBL29454253 | 0.86 | TAAR1 (0.45) | MPOTAAR1ADCY10IDO1AGXT | |
| SCHEMBL22231998 | 0.84 | MPO (0.44) | MPOTAAR1IDO1 | |
| SCHEMBL22232614 | 0.84 | PNMT (0.46) | PNMTMPOTAAR1ADCY10CYP3A4 | |
| SCHEMBL22232191 | 0.83 | MEN1 (0.44) | MPOTAAR1ADCY10CYP3A4MAPT | |
| SCHEMBL29454245 | 0.83 | MEN1 (0.44) | MPOTAAR1ADCY10CYP3A4MAPT | |
| SCHEMBL22231768 | 0.82 | TAAR1 (0.41) | TAAR1IDO1AGXTMAPK1 | |
| SCHEMBL22232481 | 0.79 | MAPT (0.42) | PNMTMPOTAAR1ADCY10CYP3A4 | |
| SCHEMBL29454347 | 0.79 | MAPT (0.42) | PNMTMPOTAAR1ADCY10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | PI INDUSTRIES LTD. (IN) | 2026-02-10 | — | — | US | disclosed |
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089523-A1 | 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF | H1-3, PRMT7, PFAS | PNMT 103/4885MPO 1451/4885TAAR1 1374/4885 |
| US-12545639-B2 | 3-substituted phenylamidine compounds, preparation and use thereof | CBR1, CBR3, HCCS | PNMT 731/4885MPO 2443/4885TAAR1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.